article thumbnail

What’s the next step in big data and AI?

Drug Discovery World

Big data and AI are all the rage. But, beyond these buzzwords and the quantity of data, what’s next for these powerful tools? His work provides insight into AI and big data in relation to pharma and drug discovery– now and in the future. “AI

article thumbnail

Pioneering access to complex generic products 

Drug Discovery World

Claire D’Abreau-Hayling, Chief Scientific Officer at Sandoz, examines how generic products can relieve industry pressure and improve access to essential medicines. Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost. Complex generics comprise a diverse range of products.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

5 Top Emerging Pharmacovigilance Startups Impacting The Industry

Cloudbyz

Time is also of the essence in drug development, as competitive product-to-market lead times help pharma companies improve profitability. With the advancement in digital technologies, data collection from end-users enables pharma companies to take notice of certain trends.

article thumbnail

EMA pilot will see if clinical trial data should be digested ‘raw’

pharmaphorum

It has been quick to give reassurance that any analysis of patient data will comply with the EU’s data protection requirements. “Access to raw data can assist regulators in understanding the submitted evidence and therefore inform the regulatory decisions on the benefit-risk balance of the product,” it continues.

article thumbnail

The new technologies strengthening pharmaceutical supply chains

Pharmaceutical Technology

According to a recent GlobalData report, healthcare professionals have – for the second year in a row – ranked artificial intelligence (AI) and Big Data as the top two technologies revolutionising the pharmaceutical sector. The legacy of this disruption has been a rethink in the way pharma companies do business.

Big Data 130
article thumbnail

A history of AstraZeneca

pharmaphorum

But although it was dubbed a “dangerous game”, some companies came out on top… On 6th April 1999, two companies with similar science-based cultures and a shared vision of the pharmaceutical industry came together to form what’s now considered as one of the top ten pharma companies in the world: AstraZeneca.

article thumbnail

Using technology to reassess the clinical trial landscape

pharmaphorum

. “The goal is to look at the primary endpoints of pain intensity and pain interference, but we’re also looking to fill in additional clinical and health economic gaps to understand the true value of our product within healthcare,” Sackman explains.